Lu-AAZTA-NI-PSMA-093
Product Specifications
Target
Others
Related Pathways
Others
Bioactivity
Lu-AAZTA-NI-PSMA-093, a bivalent radiopharmaceutical agent designed for prostate cancer treatment, improves tumor targeting and retention. This is achieved by integrating a hypoxia-sensitive nitroimidazole (NI) group with a prostate-specific membrane antigen (PSMA) targeting moiety.
Molecular Formula
C63H82LuN14O26
Molecular Weight
1626.37
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740257-500 1x 500 µL
Cytokeratin, HMW (AE-3), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400177-500 1x 500 µL
CD50 (ICAM-3) (101-1D2), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880270-500 1x 500 µL
Fibronectin (HFN7.1), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041003-100 1x 100 µL
Mucin 5AC (MUC5AC) (58M1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470050-500 1x 500 µL
IgA Secretory Component (SC05), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880034-500 1x 500 µL
Cytokeratin 8/18 (C-51), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details